Biogen Inc. (BIIB)
| Market Cap | 31.00B +64.0% |
| Revenue (ttm) | 10.03B +0.3% |
| Net Income | 834.60M -45.5% |
| EPS | 5.64 -46.1% |
| Shares Out | 147.75M |
| PE Ratio | 37.21 |
| Forward PE | 15.83 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 554,664 |
| Open | 210.01 |
| Previous Close | 210.65 |
| Day's Range | 208.22 - 210.79 |
| 52-Week Range | 131.52 - 219.72 |
| Beta | 0.16 |
| Analysts | Buy |
| Price Target | 237.59 (+13.23%) |
| Earnings Date | Jul 29, 2026 |
About BIIB
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar refe... [Read more]
Financial Performance
In 2025, Biogen's revenue was $9.89 billion, an increase of 2.22% compared to the previous year's $9.68 billion. Earnings were $1.29 billion, a decrease of -20.79%.
Financial StatementsAnalyst Summary
According to 36 analysts, the average rating for BIIB stock is "Buy." The 12-month stock price target is $237.59, which is an increase of 13.23% from the latest price.
News
Expert explains why healthcare is a top-performing sector
Apollon Wealth Management CIO Eric Sterner discusses how technology is driving gains in the healthcare sector on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbus...
Biogen Completes Acquisition of RayThera Inc.
CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on dis...
Biogen Earnings Call Transcript: Q2 2026
Q2 2026 saw strong revenue growth, driven by the expanding growth portfolio and successful integration of Apellis products. The company raised its full-year guidance, highlighted robust late-stage pipeline progress, and expects continued top- and bottom-line growth, with key data readouts and product launches ahead.
Biogen Slides: Q2 2026
Biogen has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.
Biogen Earnings release: Q2 2026
Biogen released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Biogen Quarterly report: Q2 2026
Biogen has published its Q2 2026 quarterly earnings report on July 29, 2026.
Biogen Cuts FY Adjusted View as Profit Declines
Biogen's second-quarter profit plummeted and the biopharmaceutical company cut its full-year adjusted earnings forecast.
Biogen beats quarterly estimates as newer drugs fuel growth
Biogen reported second-quarter profit and revenue that topped Wall Street estimates on Wednesday, driven by strong demand for its rare-disease medicines, while sales of its legacy multiple sclerosis ...
Biogen Raises Earnings Guidance as Growth Portfolio Outpaces Legacy Blockbuster Drugs
Biogen's growth portfolio, which includes one closely watched Alzheimer's drug, is a bright spot in the second quarter.
Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide
Virtual-first, multidisciplinary care model delivers care for adults living with ataxias, connecting them to expert neurologist options nationwide. CHICAGO, July 16, 2026 /PRNewswire/ -- Synapticure, ...
Biogen Appoints Michael J. Parini as Chief Legal Officer
CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Michael J. Parini as Chief Legal Officer, effective August 3, 2026. Parini will serve ...
Biogen Transcript: Alzheimer’s Association International Conference (AAIC Meeting) 2026
Diranersen showed robust tau reduction and cognitive benefits in early Alzheimer's, with the 60 mg twice-yearly dose emerging as optimal. Safety was favorable, and high patient retention supports advancing to phase III, with long-term data and further regulatory engagement planned.
Biogen Slides: FY 2026
Biogen has posted slides in relation to its FY 2026 quarterly earnings report, which was published on July 14, 2026.
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
Real-World Findings Support Long-Term Benefits of Continuous Treatment with LEQEMBI and Provide Important Insights into Treatment Experience Outside of a Clinical Trial Setting TOKYO and CAMBRIDGE, Ma...
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed
The lowest dose of Biogen's anti-tau Alzheimer's drug diranersen, which missed its primary goal in a midstage trial, reduced cognitive decline in five of six Alzheimer's assessment tools and signific...
Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease
CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced data from the Phase 2 CELIA study evaluating diranersen, an investigational antisense oligonucleotide (AS...
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in the U.S.) U.S. launch of LEQEMBI IQLIK as an initiation dose ...
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug
The U.S. FDA on Monday approved an at-home starting dose of Eisai's and Biogen's Alzheimer's drug, allowing some patients to begin therapy with injections administered by themselves or a caregiver.
Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer's Drug Study Details
Biogen stock receives a bullish upgrade based on expectations the market will cheer the company's detailed data on its experimental Alzheimer's drug.
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference® (AAIC®) 2026
New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and care partners TOKYO and CAMBRIDGE,...
Old cancer drug may help restore fertility for certain women
We also cover a large study that should allay fears of people who should be taking cholesterol-lowering statins.
Biogen to Highlight Breadth of Alzheimer's Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen
CAMBRIDGE, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced it will present new data across its Alzheimer's disease portfolio at the Alzheimer's Association Internat...
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout
Biogen said on Friday it had either paused or discontinued funding for most of Apellis Pharmaceuticals' research programs as it integrates the rare-disease drugs specialist it purchased for $5.6 bil...
Biogen to acquire RayThera for $1 billion
Biogen said on Wednesday it would acquire drug discovery company RayThera for $1 billion, including milestone payments.
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
Acquisition adds multiple immunology assets to Biogen's portfolio, including a lead asset poised to enter Phase 1 development Acquisition adds multiple immunology assets to Biogen's portfolio, includi...